Trademarks Filed by ZOLAB PHARMA PRIVATE LIMITED DIR. SUBHASH CHANDER

4 trademark applications recorded in the national registry under this applicant name.

The IP India register records 4 trademark applications filed by ZOLAB PHARMA PRIVATE LIMITED DIR. SUBHASH CHANDER. The single filing on record is dated 17 December 2020. The portfolio is concentrated in Class 5 — Pharmaceuticals, which accounts for 100.0% of the filings. The most common registry status across the portfolio is DRAFT (3 marks).

4Applications
1Classes covered
Dec 2020First filing
Dec 2020Latest filing

Classes ZOLAB PHARMA PRIVATE LIMITED DIR. SUBHASH CHANDER Has Filed In

NICE classes ranked by applications filed under this name. Indian trademark protection extends only to the classes actually filed in — a class absent from this table is not covered by these registrations.
NICE classShare of portfolioApplications
Class 5 — Pharmaceuticals4 (100%)

Registry Status of These Filings

Status is the free-text value the registry records against each application. "Unknown" means no status had been published for that record at the last refresh.
StatusShare of portfolioApplications
DRAFT3 (75%)
Unknown1 (25%)

All Trademarks Filed by ZOLAB PHARMA PRIVATE LIMITED DIR. SUBHASH CHANDER

Every trademark application the register attributes to ZOLAB PHARMA PRIVATE LIMITED DIR. SUBHASH CHANDER, newest filing first. Each row links to that mark's full registry record.

  1. EBUZOL
    App. No. 4784505Class 5Filed 17 Dec 2020
  2. OSZEM
    App. No. 4784504Class 5Filed 17 Dec 2020
    DRAFT
  3. ZOLNERVE
    App. No. 4784503Class 5Filed 17 Dec 2020
    DRAFT
  4. ZOLIXIB
    App. No. 4784501Class 5Filed 17 Dec 2020
    DRAFT

About this data

Source
Sourced from the official IP India trademark register and the Trade Marks Journal. Only records published by the registry are counted — never applications filed through Trademarx.
Grouped by
The applicant name recorded on each application, normalised for case, spacing and punctuation — so "ZOLAB PHARMA PRIVATE LIMITED DIR. SUBHASH CHANDER" and its other recorded spellings appear together on this page.
Refreshed
Hourly.
Known limitation
Marks a business holds under a group company, a subsidiary, or a founder's personal name are recorded against those names and appear on their own pages, not here.

Frequently asked questions

How many trademarks does ZOLAB PHARMA PRIVATE LIMITED DIR. SUBHASH CHANDER have?

4 trademark applications in the IP India register are filed under the name ZOLAB PHARMA PRIVATE LIMITED DIR. SUBHASH CHANDER. This counts filings recorded against that applicant name; marks held under a group company, a subsidiary, or a founder's personal name are recorded separately.

Which trademark classes does ZOLAB PHARMA PRIVATE LIMITED DIR. SUBHASH CHANDER file in?

Class 5 — Pharmaceuticals is the most-used class, with 4 filings — 100.0% of the portfolio. In total the portfolio covers 1 NICE class. Indian trademark protection only extends to the classes actually filed in, so classes absent from this list are not covered by these registrations.

Can I use a brand name similar to one filed by ZOLAB PHARMA PRIVATE LIMITED DIR. SUBHASH CHANDER?

Not safely, if it is in a class this applicant already covers. A mark that is identical or deceptively similar to an earlier filing in the same or a related class can be refused by the registry or opposed after publication. Run a clearance search across the relevant classes before adopting a name.

How current is this data?

Sourced from the official IP India trademark register and the Trade Marks Journal. Only records published by the registry are counted — never applications filed through Trademarx. Status and class shown reflect what the Registry has on file at the time of the most recent refresh.

Checking a competitor, a partner, or your own portfolio?

Free clearance search, IP India authorised agents, filing from ₹1,499 + govt. fees.

Free Trademark SearchRegister a Trademark

Data sourced from the official IP India trademark registry and Trade Marks Journal, refreshed continuously. Search another company →